Argenx, the Belgian-Dutch biotech company, has lost 8.4 billion euros in market value after a setback. #Cookies #Beveiliging #Cloudflare (translated)
EVS lost 30% of its value on the Brussels stock exchange on Thursday, partly due to rising oil prices and disappointing business results. #BourseBruxelles #EVS #ArgenX (translated)

The Belgian stock exchange experienced two major declines this Thursday, with Argenx weakening the Bel 20 and EVS ending with a loss of nearly 30%, amid a pessimistic global market climate. #BourseBruxelles #Argenx #MarchésFinanciers (translated)

Argenx announced the halt of phase 3 of a clinical trial for its treatment for Sjögren's syndrome, causing a drop of more than 15% in its shares and negatively affecting the Bel 20 index. #Argenx #MaladieDeSjögren #Biopharma (translated)

Argenx a annoncé des résultats positifs pour son médicament Vyvgart, récemment en phase trois d'essai clinique pour traiter la myosite, montrant des améliorations significatives chez les patients, ce qui a entraîné une augmentation du cours de son action. #Vyvgart #myosite #Argenx
La Bourse de Bruxelles a échappé à une forte chute grâce à la performance de l'action biopharmaceutique ArgenX, qui a progressé de 5,09 % malgré une baisse générale des marchés européens, impactés par la hausse des prix du pétrole et les craintes d'un nouveau choc inflationniste. #ArgenX #marchés #inflation
